Send to

Choose Destination
Oncotarget. 2017 Dec 15;9(7):7442-7452. doi: 10.18632/oncotarget.23448. eCollection 2018 Jan 26.

SALL1 expression in acute myeloid leukemia.

Author information

Georgia Regent University Cancer Center, Augusta, GA, USA.
Present address: Stony Brook University Cancer Center, Stony Brook, NY, USA.
Department of Hematology, West China hospital of Sichuan University, Chengdu, P.R. China.
Department of Nephrology, Saint Louis University, St Louis, MO, USA.


Similar signaling pathways could operate in both normal hematopoietic stem and progenitor cells (HSPCs) and leukemia stem cells (LSCs). Thus, targeting LSCs signaling without substantial toxicities to normal HSPCs remains challenging. SALL1, is a member of the transcriptional network that regulates stem cell pluripotency, and lacks significant expression in most adult tissues, including normal bone marrow (NBM). We examined the expression and functional characterization of SALL1 in NBM and in acute myeloid leukemia (AML) using in vitro and in vivo assays. We showed that SALL1 is expressed preferentially in LSCs- enriched CD34+CD38- cell subpopulation but not in NBM. SALL1 inhibition resulted in decreased cellular proliferation and in inferior AML engraftment in NSG mice and it was also associated with upregulation of PTEN and downregulation of m-TOR, β-catenin, and NF-қB expression. These findings suggest that SALL1 inhibition interrupts leukemogenesis. Further studies to validate SALL1 as a potential biomarker for minimal residual disease (MRD) and to determine SALL1's role in prognostication are ongoing. Additionally, pre-clinical evaluation of SALL1 as a therapeutic target in AML is warranted.



Conflict of interest statement

CONFLICTS OF INTEREST The authors declare that they have no conflicts of interest.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center